Post job

NovaBay Pharmaceuticals main competitors are Exelixis, Gilead Sciences, and Vertex Pharmaceuticals.

Competitor Summary. See how NovaBay Pharmaceuticals compares to its main competitors:

  • Merck has the most employees (74,000).
  • Employees at Exelixis earn more than most of the competitors, with an average yearly salary of $108,978.
Work at NovaBay Pharmaceuticals?
Share your experience

NovaBay Pharmaceuticals vs competitors

CompanyFounding dateZippia scoreHeadquarters# of LocationsRevenueEmployees
2000
3.4
Emeryville, CA1$14.4M25
1989
4.6
Boston, MA5$11.0B3,400
2002
4.6
Bridgewater, NJ6$2.8B6,500
1952
4.9
Parsippany-Troy Hills, NJ6$9.3B11,300
1995
4.3
New York, NY1$115.5M43
1891
4.6
Kenilworth, NJ31$64.2B74,000
1980
4.8
Thousand Oaks, CA9$33.4B22,000
1987
4.5
Foster City, CA9$28.8B11,800
1997
4.7
Bothell, WA3$2.0B900
1992
4.9
Rockville, MD1$131.0M1,000
1994
4.9
Alameda, CA1$2.2B484
2014
4.4
Cambridge, MA1$57.9M211
-
4.0
--$19.0M200
1991
4.8
Cambridge, MA1$118.8M380

Rate NovaBay Pharmaceuticals' competitiveness in the market.

Zippia waving zebra

NovaBay Pharmaceuticals salaries vs competitors

Among NovaBay Pharmaceuticals competitors, employees at Exelixis earn the most with an average yearly salary of $108,978.

Compare NovaBay Pharmaceuticals salaries vs competitors

CompanyAverage salaryHourly salarySalary score
NovaBay Pharmaceuticals
$84,113$40.44-
Vertex Pharmaceuticals
$95,952$46.13-
Amneal Pharmaceuticals
$76,227$36.65-
Zoetis
$87,092$41.87-
SIGA Technologies
$71,494$34.37-
Merck
$90,328$43.43-

Compare NovaBay Pharmaceuticals job title salaries vs competitors

CompanyHighest salaryHourly salary
NovaBay Pharmaceuticals
$88,326$42.46
Amgen
$101,179$48.64
Merck
$98,284$47.25
Vertex Pharmaceuticals
$95,934$46.12
Exelixis
$94,878$45.61
Gilead Sciences
$94,165$45.27
Zoetis
$94,133$45.26
Ariad Pharmaceuticals
$71,512$34.38
Inova Pharmaceuticals
$71,212$34.24
Human Genome Sciences
$69,750$33.53
Intellia Therapeutics
$68,138$32.76
SIGA Technologies
$62,933$30.26
Seagen
$59,728$28.72
Amneal Pharmaceuticals
$56,100$26.97

Do you work at NovaBay Pharmaceuticals?

Does NovaBay Pharmaceuticals effectively differentiate itself from competitors?

NovaBay Pharmaceuticals jobs

NovaBay Pharmaceuticals demographics vs competitors

Compare gender at NovaBay Pharmaceuticals vs competitors

Job titleMaleFemale
Merck54%46%
Vertex Pharmaceuticals56%44%
Gilead Sciences56%44%
Amgen57%43%
Amneal Pharmaceuticals64%36%
NovaBay Pharmaceuticals--
Male
Female
100%
75%
50%
25%
0%
0%
25%
50%
75%
100%

Compare race at NovaBay Pharmaceuticals vs competitors

CompanyWhiteHispanic or LatinoBlack or African AmericanAsianUnknownDiversity score
49%24%7%15%5%
9.7
44%20%8%23%6%
9.8
56%16%10%14%4%
9.8
56%14%7%17%6%
9.7
36%13%7%35%10%
9.7
58%9%7%22%5%
9.2

NovaBay Pharmaceuticals revenue vs competitors

NovaBay Pharmaceuticals revenue is $14.4M. Among it's competitors, the company with the highest revenue is Merck, $64.2B . The company with the lowest revenue is Inova Pharmaceuticals, $19.0M.

NovaBay Pharmaceuticals and similar companies CEOs

CEOBio
Robert A. Bradway
Amgen

Robert A. Bradway is an American businessman. He is the chairman and chief executive officer of Amgen.

Michael M. Morrissey Ph.d
Exelixis

Michael Morrissey is a President/CEO at EXELIXIS, INC.; Board Member at EXELIXIS, INC.; and Board Member at XW LABORATORIES INC and is based in Danville, California. He has experience at Schering AG and has worked as VP:Discovery Research at Berlex Biosciences; Senior Scientist at Novartis; and Senior VP:Discovery at EXELIXIS, INC.. Michael studied at Harvard University and University of Wisconsin Oshkosh.

Daniel O’Day
Gilead Sciences

Robert M. Davis
Merck

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

Roger D. Dansey
Seagen

Reshma Kewalramani M.d
Vertex Pharmaceuticals

Reshma Kewalramani (born 1973), is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. She is the first female CEO of a large US biotech company. She was previously the chief medical officer and vice president of global medicines development and medical affairs at Vertex.

Juan Ramón Alaix
Zoetis

Juan Ramón Alaix was appointed chief executive officer of Zoetis in July 2012. In this role, he leads the world’s largest company with a singular focus on animal health medicines and vaccines. He is a member of the Zoetis Board of Directors. Mr. Alaix served as President of Pfizer Animal Health since 2006, where he was responsible for the overall strategic direction and financial performance of the company. Under his leadership, the company generated annual revenue of $4.8 billion in 2015 with approximately 9,000 employees worldwide. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. He joined Pfizer from Pharmacia in 2003 as Regional President. He has 35 years’ experience of increasing responsibility in finance, commercial and management, including 20 years in the pharmaceutical industry. In the 1990s, Mr. Alaix served in general management with Rhône-Poulenc Rorer in Spain and Belgium before becoming country President of Spain for Pharmacia in 1998. In 2013, Mr. Alaix completed a two-year term as President of the International Federation for Animal Health (IFAH), now known as HealthforAnimals, in addition to serving as a member of the board and executive committee. HealthforAnimals represents manufacturers of veterinary medicines, vaccines and other animal health products in both developed and emerging markets. Mr. Alaix continues to serve as a member of the HealthforAnimals board and executive committee. A native of Spain, Mr. Alaix received a graduate degree in economics from the Universidad de Madrid.

Chirag K. Patel
Amneal Pharmaceuticals

Mr. Patel’s lifelong drive and constant desire to discover what’s next has carried Amneal Pharmaceuticals from humble beginnings to an emerging global presence. Patel is the recipient of several industry honors including the 2011 Ernst & Young National Entrepreneur of the Year Life Sciences Award® and supports various philanthropic and charitable causes both in the US and abroad. Patel and his wife, Priti Patel, established the Niswarth Children Foundation in 2013, with the goal of bringing fresh water, sanitation, sustenance, and education to one million underprivileged children. Patel received his bachelor’s degree in commerce from H.A. College of Commerce, India, and his Bachelor of Science in business administration from New Jersey City University. He also received an honorary degree of doctor of humane letters from New Jersey City University in recognition of his efforts to serve others and help them transform their lives. Patel serves on the boards of the Generic Pharmaceutical Association, the Art of Living Foundation, the New Jersey City University Foundation, and the Family Reach Foundation.

Paris Panayiotopoulos
Ariad Pharmaceuticals

NovaBay Pharmaceuticals competitors FAQs

Search for jobs